Expres2ion Biotech Holding Stock Beta
| EXPRS2 Stock | SEK 19.24 0.66 3.32% |
ExpreS2ion Biotech Holding fundamentals help investors to digest information that contributes to ExpreS2ion Biotech's financial success or failures. It also enables traders to predict the movement of ExpreS2ion Stock. The fundamental analysis module provides a way to measure ExpreS2ion Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ExpreS2ion Biotech stock.
ExpreS2ion |
ExpreS2ion Biotech Holding Company Beta Analysis
ExpreS2ion Biotech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current ExpreS2ion Biotech Beta | 1.25 |
Most of ExpreS2ion Biotech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ExpreS2ion Biotech Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, ExpreS2ion Biotech Holding has a Beta of 1.2489. This is 45.22% higher than that of the Healthcare sector and 10.15% lower than that of the Biotechnology industry. The beta for all Sweden stocks is notably lower than that of the firm.
ExpreS2ion Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ExpreS2ion Biotech's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ExpreS2ion Biotech could also be used in its relative valuation, which is a method of valuing ExpreS2ion Biotech by comparing valuation metrics of similar companies.ExpreS2ion Biotech is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ExpreS2ion Biotech will likely underperform.
ExpreS2ion Fundamentals
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (20.75) % | |||
| Current Valuation | 361.15 M | |||
| Shares Outstanding | 37.15 M | |||
| Shares Owned By Institutions | 1.75 % | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 55.94 X | |||
| Revenue | 12.23 M | |||
| Gross Profit | 1.07 M | |||
| EBITDA | (45.5 M) | |||
| Net Income | (43.92 M) | |||
| Cash And Equivalents | 10.14 M | |||
| Cash Per Share | 0.75 X | |||
| Total Debt | 3.48 M | |||
| Debt To Equity | 10.40 % | |||
| Current Ratio | 2.62 X | |||
| Book Value Per Share | 2.75 X | |||
| Cash Flow From Operations | (45.65 M) | |||
| Earnings Per Share | (1.55) X | |||
| Number Of Employees | 14 | |||
| Beta | 1.25 | |||
| Market Capitalization | 487.85 M | |||
| Total Asset | 151.96 M | |||
| Z Score | 84.0 | |||
| Net Asset | 151.96 M |
About ExpreS2ion Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ExpreS2ion Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ExpreS2ion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ExpreS2ion Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in ExpreS2ion Stock
ExpreS2ion Biotech financial ratios help investors to determine whether ExpreS2ion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ExpreS2ion with respect to the benefits of owning ExpreS2ion Biotech security.